NASDAQ:PGEN Precigen (PGEN) Stock Price, News & Analysis $4.55 -0.04 (-0.87%) Closing price 04:00 PM EasternExtended Trading$4.57 +0.02 (+0.44%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Precigen Stock (NASDAQ:PGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Precigen alerts:Sign Up Key Stats Today's Range$4.49▼$4.8250-Day Range$1.42▼$4.5952-Week Range$0.65▼$4.82Volume10.26 million shsAverage Volume16.49 million shsMarket Capitalization$1.36 billionP/E RatioN/ADividend YieldN/APrice Target$8.25Consensus RatingModerate Buy Company Overview Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. Read More Precigen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScorePGEN MarketRank™: Precigen scored higher than 77% of companies evaluated by MarketBeat, and ranked 240th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingPrecigen has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePrecigen has only been the subject of 4 research reports in the past 90 days.Read more about Precigen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Precigen are expected to grow in the coming year, from ($0.32) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precigen is -10.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precigen is -10.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Precigen's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.71% of the float of Precigen has been sold short.Short Interest Ratio / Days to CoverPrecigen has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Precigen has recently increased by 1.41%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrecigen does not currently pay a dividend.Dividend GrowthPrecigen does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.77 Percentage of Shares Shorted19.71% of the float of Precigen has been sold short.Short Interest Ratio / Days to CoverPrecigen has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Precigen has recently increased by 1.41%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment0.46 News SentimentPrecigen has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Precigen this week, compared to 3 articles on an average week.Search Interest39 people have searched for PGEN on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.MarketBeat Follows6 people have added Precigen to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Precigen insiders have not sold or bought any company stock.Percentage Held by Insiders47.10% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 33.51% of the stock of Precigen is held by institutions.Read more about Precigen's insider trading history. Receive PGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PGEN Stock News HeadlinesPrecigen (PGEN) Is Up 32.3% After FDA Approval of First Therapy for Recurrent Respiratory PapillomatosisAugust 27 at 9:53 AM | finance.yahoo.comCitizens JMP Raises PT on Precigen from $6 to $8, Keeps Outperform RatingAugust 26 at 10:13 AM | insidermonkey.comCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.August 28 at 2:00 AM | SmartAsset (Ad)H.C. Wainwright Remains Bullish on Precigen (PGEN)August 26 at 4:57 AM | finance.yahoo.comPrecigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. WainwrightAugust 25 at 8:05 AM | prnewswire.comAnalysts Set Precigen, Inc. (NASDAQ:PGEN) Target Price at $8.25August 24, 2025 | americanbankingnews.comPrecigen Inc. (PGEN) Stock Price Today - WSJAugust 22, 2025 | wsj.comPrecigen Target of Unusually High Options Trading (NASDAQ:PGEN)August 22, 2025 | americanbankingnews.comSee More Headlines PGEN Stock Analysis - Frequently Asked Questions How have PGEN shares performed this year? Precigen's stock was trading at $1.12 at the start of the year. Since then, PGEN shares have increased by 306.3% and is now trading at $4.55. How were Precigen's earnings last quarter? Precigen, Inc. (NASDAQ:PGEN) released its quarterly earnings data on Tuesday, August, 12th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. The biotechnology company earned $0.86 million during the quarter, compared to analysts' expectations of $0.67 million. Precigen had a negative net margin of 2,868.66% and a negative trailing twelve-month return on equity of 842.83%. Who are Precigen's major shareholders? Top institutional shareholders of Precigen include Patient Capital Management LLC (5.51%), Geode Capital Management LLC (1.27%), Bank of America Corp DE (0.28%) and JPMorgan Chase & Co. (0.26%). Insiders that own company stock include Helen Sabzevari, Randal J Kirk, Steven Frank, Jeffrey Thomas Perez, Donald P Lehr, Dean J Mitchell, Harry Jr Thomasian and Rutul R Shah. View institutional ownership trends. How do I buy shares of Precigen? Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Precigen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Precigen investors own include Nordic American Tankers (NAT), ZIOPHARM Oncology (ZIOP), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Hess (HES) and Boeing (BA). Company Calendar Last Earnings8/12/2025Today8/28/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PGEN CIK1356090 Webwww.precigen.com Phone(301) 556-9900FaxN/AEmployees190Year FoundedN/APrice Target and Rating Average Price Target for Precigen$8.25 High Price Target$8.50 Low Price Target$8.00 Potential Upside/Downside+81.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$126.24 million Net Margins-2,868.66% Pretax Margin-2,870.32% Return on Equity-842.83% Return on Assets-78.98% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.71 Sales & Book Value Annual Sales$3.92 million Price / Sales346.24 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-37.96Miscellaneous Outstanding Shares297,970,000Free Float157,628,000Market Cap$1.36 billion OptionableOptionable Beta1.87 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:PGEN) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.